Today we announced the launch of Matchpoint Therapeutics - founded to harness the power of covalency to develop precision small molecule medicines for immune diseases. Check out the press release here. bit.ly/3S2nFOf

At Matchpoint we’re exclusively developing covalent medicines and have set our sights on transforming the treatment of serious immune diseases. bit.ly/3S2nFOf

Our Co-founder Nathanael Gray shares his thoughts on where our platform can go, and how it has the potential to screen for highly selective medicines early in the discovery process. bit.ly/3S2nFOf

The resurgence of covalent medicines ~15 years ago led to important medicines. With our Series A, we are building on this legacy by deploying the power of covalency to the field of immunology. Chairman of our BOD, Bruce Booth, comments. bit.ly/3S2nFOf Bruce Booth

Edward Chouchani comments on how our ACE platform can overcome the challenges that previously limited the development of precision covalent medicines. bit.ly/3S2nFOf

Matchpoint brings together passionate drug hunters, technical experts, and seasoned company builders - unified by our values and the goal of developing precision covalent medicines that transform the lives of those impacted by serious disease. matchpointtx.com

Wishing everyone a Happy Thanksgiving from the team at Matchpoint - which we’re very thankful for!

Wishing everyone a wonderful holiday season from the team at Matchpoint!

We’re thrilled to be working with Novartis to develop oral covalent inhibitors directed at a transcription factor, and historically hard-to-drug protein, linked to a number of inflammatory diseases. bit.ly/40vzkfJ